Copyright
©2008 The WJG Press and Baishideng.
World J Gastroenterol. Jan 14, 2008; 14(2): 255-259
Published online Jan 14, 2008. doi: 10.3748/wjg.14.255
Published online Jan 14, 2008. doi: 10.3748/wjg.14.255
Table 1 Demographic and clinical features of study patients
| Variables | Group A (n = 22) | Group-B (n = 14) | P |
| Age (yr) | 35.2 ± 12.1 | 37.1 ± 14.6 | 0.629 |
| Male (%) | 12 (54.5) | 10 (71.4) | 0.448 |
| BMI (kg/m2) | 25.6 ± 3.3 | 26.1 ± 3.9 | 0.78 |
| ALT (IU/L)-Range | 59.2 ± 22.4-(33-109) | 44.8 ± 20.9-(21-71) | 0.489 |
| Viral load (x 105 copy/mL) | 7.9 ± 4.8 | 8.1 ± 4.5 | 0.89 |
| Genotype 1b (%) | 86.4 | 92.9 | 0.56 |
| HD duration (mo) | 52.4 ± 24.7 | 49.8 ± 21.1 | 0.95 |
- Citation: Ayaz C, Celen MK, Yuce UN, Geyik MF. Efficacy and safety of pegylated-interferon α-2a in hemodialysis patients with chronic hepatitis C. World J Gastroenterol 2008; 14(2): 255-259
- URL: https://www.wjgnet.com/1007-9327/full/v14/i2/255.htm
- DOI: https://dx.doi.org/10.3748/wjg.14.255